Rational Pharmacotherapy in Cardiology

Advanced search

Hepcidin as a Regulator of Iron Metabolism and Mediator of Inflammation in Patients with Chronic Heart Failure and Anemia of Chronic Diseases of the Elderly and Senile Age


Aim. To study the role of hepcidin as a regulator of iron metabolism and a mediator of inflammation in elderly and senile patients with chronic heart failure (CHF) with anemia of chronic diseases (ACD).
Material and methods. The levels of hemogram parameters, ferrokinetics (serum iron, ferritin, transferrin, erythropoietin, hepcidin), inflammation [C-reactive protein (CRP), interleukin-6 (IL-6)], as well as correlations between hepcidin and these parameters were studied in patients with CHF with ACD (n=35), with CHF without anemia (n=35) and in elderly and senile patients without CHF and anemia (control group; n=20).
Results. Normal levels of hepcidin (9.17±0.97 ng/ml) and the only significant correlation of hepcidin with the ferrokinetic parameter – serum iron [r(S)=0.480, p<0.05] were found in the control group. Normal levels of hepcidin (12.01±1.19 ng/ml) and two significant correlations of hepcidin with the ferrokinetic parameter – ferritin [r(S)=0.525, p<0.05] and transferrin [r(S)=-0.343, p<0.05] were found in the CHF without anemia group. Significantly elevated levels of hepcidin (23.81±3.63 ng/ml) were found in the CHF with ACD group compared to the CHF without anemia group (p=0.008) and the control group (p=0.003). Also, five significant correlations of hepcidin with hemogram parameters – hemoglobin [r(S)=-0.461, p<0.05] and the average concentration of hemoglobin in the erythrocyte [r(S)=-0.437, p<0.05]; with ferrokinetic parameters – ferritin [r(S)=0.596,
p<0.05] and transferrin [r(S)=-0.474, p<0.05]; with inflammation parameters – CRP [r(S)=0.561, p<0.05] were found in the CHF with ACD group.
Conclusion. The increased level of hepcidin in CHF patients with ACD and the formation of links of hepcidin with indicators of inflammation reflect its role as a mediator of inflammation, and the formation of connections with indicators of hemogram and ferrokinetics – its role as a regulator of iron metabolism involved in the development of ACD in elderly and senile CHF patients.

About the Authors

N. I. Solomakhina
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

 Nina I. Solomakhina



A. S. Lishuta
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation

 Alexey S. Lishuta 


A. V. Dementieva
Hospital for War Veterans No. 1 of the Moscow Department of Health
Russian Federation

 Anna V. Dementieva 



1. Park CH, Valore EV, Waring AJ, Ganz T. Hepcidin, a Urinary Antimicrobial Peptide Synthesized in the Liver. J Biol Chem. 2001;276(11):7806-10. DOI:10.1074/jbc.M008922200.

2. Camaschella С. Iron and hepcidin: a story of recycling and balance. Hematology Am Soc Hematol Educ Program. 2013;2013:1-8. DOI:10.1182/asheducation-2013.1.1.

3. Arezes J, Nemeth E. Hepcidin and Iron Disorders: New Biology and Clinical Approaches. Int J Lab Hematol. 2015;37(1):92-8. DOI:10.1111/ijlh.12358.

4. Nemeth E, Valore EV, Territo M, et al. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101(7):2461-3. DOI:10.1182/blood-2002-10-3235.

5. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113(9):1271-6. DOI:10.1172/JCI20945.

6. D’Angelo G. Role of hepcidin in the pathophysiology and diagnosis of anemia. Blood Res. 2013;48(1):10-5. DOI:10.5045/br.2013.48.1.10.

7. Drakesmith H, Prentice AM. Hepcidin and the iron-infection axis. Science. 2012;338(6108):768-72. DOI:10.1126/science.1224577.

8. Briasoulis A, Androulakis E, Christophides T, Tousoulis D. The Role of Inflammation and Cell Death in the Pathogenesis, Progression and Treatment of Heart Failure. Heart Fail Rev. 2016;21(2):169-76. DOI:10.1007/s10741-016-9533-z.

9. Matsumoto M, Tsujino T, Lee-Kawabata M, et al. Iron Regulatory Hormone Hepcidin Decreases in Chronic Heart Failure Patients With Anemia. Circ J. 2010;74(2):301-6. DOI:10.1253/circj.cj-09-0663.

10. Anand IS, Rector TS. Pathogenesis of Anemia in Heart Failure. Circ Heart Fail. 2014;7(5):699-700. DOI:10.1161/CIRCHEARTFAILURE.114.001645.

11. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med. 2005;352(10):1011-23. DOI:10.1056/NEJMra041809. PMID: 15758012.

12. Leong W, Lönnerdal B. Hepcidin, the Recently Identified Peptide That Appears to Regulate Iron Absorption. J Nutr. 2004;134(1):1-4. DOI:10.1093/jn/134.1.1.

13. Dick SA, Epelman S. Chronic Heart Failure and Inflammation What Do We Really Know? Circ Res. 2016;119(1):159-76. DOI:10.1161/CIRCRESAHA.116.308030.

14. Hage C, Michaëlsson E, Linde C, et al. Inflammatory Biomarkers Predict Heart Failure Severity and Prognosis in Patients With Heart Failure With Preserved Ejection Fraction A Holistic Proteomic Approach. Circ Cardiovasc Genet. 2017;10(1):e001633. DOI:10.1161/CIRCGENETICS.116.001633.

15. Boulognea M, Sadouneb M, Launaybc JM, et al. Inflammation versus mechanical stretch biomarkers over time in acutely decompensated heart failure with reduced ejection fraction. Int J Cardiol. 2017;226:53-59. DOI:10.1016/j.ijcard.2016.10.038.

16. Van der Putten K, Jie KE, Van den Broek D, et al. Hepcidin-25 is a marker of the response rather than resistance to exogenous erythropoietin in chronic kidney disease/chronic heart failure patients. Eur J Heart Fail. 2010;12(9):943-50. DOI:10.1093/eurjhf/hfq099.

17. Divakaran V, Mehta S, Yao D, et al. Hepcidin in anemia of chronic heart failure. Am J Hematol. 2011;86(1):107-9. DOI:10.1002/ajh.21902.

18. Jankowska ЕА, Malyszko J, Ardehali H, et al. Iron status in patients with chronic heart failure. Eur Heart J. 2013;34(11):827-34. DOI:10.1093/eurheartj/ehs377.

19. Podzolkov VI, Dragomiretskaya NA, Stolbova SK, Rusinov IS. Associations of NT-proBNP and hepcidin levels with clinical and laboratory parameters in patients with heart failure with various severity of left ventricular systolic dysfunction. Cardiovascular Therapy and Prevention. 2020;19(4):2587 (In Russ.) DOI:10.15829/1728-8800-2020-2587.

20. Nemeth E. Targeting the Hepcidin-Ferroportin Axis in the Diagnosis and Treatment of Anemias. Adv Hematol. 2010;2010:750643. DOI:10.1155/2010/750643.

21. Lanser L, Fuchs D, Scharnagl H, et al. Anemia of Chronic Disease in Patients With Cardiovascular Disease. Front Cardiovasc Med. 2021;8:666638. DOI:10.3389/fcvm.2021.666638.

22. Muzzarelli S, Pfisterer M, TIME Investigators. Anemia as Independent Predictor of Major Events in Elderly Patients With Chronic Angina. Am Heart J. 2006;152(5):991-6. DOI:10.1016/j.ahj.2006.06.014.

23. Caughey MC, Avery CL, Ni H, et al. Outcomes of patients with anemia and acute decompensated heart failure with preserved versus reduced ejection fraction (from the ARIC study community surveillance). Am J Cardiol. 2014;114(12):1850-4. DOI:10.1016/j.amjcard.2014.09.024.

24. Muñoz M, García-Erce JA, Remacha AF. Disorders of Iron Metabolism. Part II: Iron Deficiency and Iron Overload. J Clin Pathol. 2011;64(4):287-96. DOI:10.1136/jcp.2010.086991.

25. Cook JD. Diagnosis and Management of Iron-Deficiency Anaemia. Best Pract Res Clin Haematol. 2005;18(2):319-32. DOI:10.1016/j.beha.2004.08.022.

26. Drozd M, Jankowska EA, Banasiak W, Ponikowski P. Iron Therapy in Patients With Heart Failure and Iron Deficiency: Review of Iron Preparations for Practitioners. Am J Cardiovasc Drugs. 2017;17(3):183-201. DOI:10.1007/s40256-016-0211-2.

27. Inker LA, Astor BC, Fox CH, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD. Am J Kidney Dis. 2014;63(5):713-35. DOI:10.1053/j.ajkd.2014.01.416.

28. Benjamini Y, Yekutieli D. The control of the false discovery rate in multiple testing under dependency. Annals of Statistics. 29(4):1165-1188. DOI:10.1214/aos/1013699998.

29. Nanas JN, Matsouka C, Karageorgopoulos D, et al. Etiology of Anemia in Patients With Advanced Heart Failure. J Am Coll Cardiol. 2006;48(12):2485-9. DOI:10.1016/j.jacc.2006.08.034.

30. Nairz M, Theurl I, Wolf D, Weiss G. Iron deficiency or anemia of inflammation? Differential diagnosis and mechanisms of anemia of inflammation. Wien Med Wochenschr. 2016;166(13-14):411-423. DOI:10.1007/s10354-016-0505-7.

31. Nagai T, Nishimura K, Honma T, et al., NaDEF investigators. Prognostic Significance of Endogenous Erythropoietin in Long-Term Outcome of Patients With Acute Decompensated Heart Failure. Eur J Heart Fail. 2016;18(7):803-13. DOI:10.1002/ejhf.537.

32. Nicolas G, Viatte L, Bennoun M, et al. Hepcidin, a new iron regulatory peptide. Blood Cells Mol Dis. 2002;29(3):327-35. DOI:10.1006/bcmd.2002.0573.

33. Wendy PJ, den Elzen, Anton JM, et al. Plasma hepcidin levels and anemia in old age. The Leiden 85-Plus Study. Haematologica. 2013;98(3):448-54. DOI:10.3324/haematol.2012.068825.

34. Cowie MR, Wood DA, Coats AJ, et al. Survival of Patients With a New Diagnosis of Heart Failure: A Population Based Study. Heart. 2000;83(5):505-10. DOI:10.1136/heart.83.5.505.

35. Picca A, Mankowski RT, Kamenov G, et al. Advanced Age Is Associated with Iron Dyshomeostasis and Mitochondrial DNA Damage in Human Skeletal Muscle. Cells. 2019;8(12):1525. DOI:10.3390/cells8121525.

36. Suega K, Widiana GR. Predicting hepcidin level using inflammation markers and iron indicators in patients with anemia of chronic disease. Hematol Transfus Cell Ther. 2019;41(4):342-348. DOI:10.1016/j.htct.2019.03.011.

37. Núñez J, Comín-Colet J, Miñana G, et al. Iron deficiency and risk of early readmission following a hospitalization for acute heart failure. Eur J Heart Fail. 2016;18(7):881. DOI:10.1002/ejhf.588.

38. Larina VN, Bart BYa, Balabanova EL. Anemic syndrome in patients with chronic heart failure. Russian Journal of Cardiology. 2010;(3):34-40 (In Russ.).

39. Arutyunov AG, Rylova AK, Arutyunov GP. Register of hospitalized patients with circulatory decompensation (Pavlovsky register). Message 1. Modern clinical characteristics of a patient with circulatory decompensation. Clinical phenotypes of patients. Heart Failure. 2014;82(1):23-32 (In Russ.).

40. Tkachenko EI, Borovkova NYu, Buyanova MV, Borovkov NN. Cytokine-induced inflammation in anemia in patients with chronic heart failure. Clinical Medicine (Russian Journal). 2020;98(2):122-9 (In Russ.). DOI:10.30629/0023-2149-2020-98-2-122-129.

41. den ElzenWP, deCraen AJ, Wiegerinck ET, et al. Plasma hepcidin levels and anemia in old age. The Leiden 85-Plus Study. Haematologica. 2013;98(3):448-54. DOI:10.3324/haematol.2012.068825.


For citations:

Solomakhina N.I., Lishuta A.S., Dementieva A.V. Hepcidin as a Regulator of Iron Metabolism and Mediator of Inflammation in Patients with Chronic Heart Failure and Anemia of Chronic Diseases of the Elderly and Senile Age. Rational Pharmacotherapy in Cardiology. 2022;18(5):553-563. (In Russ.)

Views: 647

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)